Articles with "safety novel" as a keyword



Photo from wikipedia

Utility and Safety of a Novel Fully Covered Metal Stent in Unresectable Distal Malignant Biliary Obstruction

Sign Up to like & get
recommendations!
Published in 2020 at "Digestive Diseases and Sciences"

DOI: 10.1007/s10620-020-06114-8

Abstract: Background Self-expandable metal stents (SEMSs) are widely used in patients with distal malignant biliary obstruction. A SEMS that can avoid occlusion as much as possible is desirable. Aims The aim of this multicenter single-arm prospective… read more here.

Keywords: obstruction; safety novel; distal malignant; biliary obstruction ... See more keywords
Photo from wikipedia

Immunogenicity and Safety of a Novel 13-Valent Pneumococcal Vaccine in Healthy Chinese Infants and Toddlers

Sign Up to like & get
recommendations!
Published in 2022 at "Frontiers in Microbiology"

DOI: 10.3389/fmicb.2022.870973

Abstract: Background To determine the non-inferiority of the seven common serotypes (4, 6B, 9V, 14, 18C, 19F, and 23F) in the 13-valent pneumococcal conjugate vaccine (PCV13) with each serotype conjugated to a tetanus toxoid carrier protein… read more here.

Keywords: valent pneumococcal; immunogenicity safety; safety; novel valent ... See more keywords
Photo from wikipedia

Methylsulfonylmethane: Applications and Safety of a Novel Dietary Supplement

Sign Up to like & get
recommendations!
Published in 2017 at "Nutrients"

DOI: 10.3390/nu9030290

Abstract: Methylsulfonylmethane (MSM) has become a popular dietary supplement used for a variety of purposes, including its most common use as an anti-inflammatory agent. It has been well-investigated in animal models, as well as in human… read more here.

Keywords: supplement; safety novel; applications safety; dietary supplement ... See more keywords
Photo by nampoh from unsplash

Cardiovascular safety of novel non-small cell lung cancer oncotherapy in a patient treated with novel generations of tyrosine kinase inhibitors.

Sign Up to like & get
recommendations!
Published in 2018 at "Kardiologia polska"

DOI: 10.5603/kp.2018.0061

Abstract: Figure 2. Changes in the cardiac parameters during treatment with tyrosine kinase inhibitors; DBP — diastolic blood pressure; HR — heart rate; LVEF — left ventricular ejection fraction; NT-proBNP — N-terminal-pro B-type natriuretic peptide; SBP… read more here.

Keywords: kinase inhibitors; safety novel; novel non; cardiovascular safety ... See more keywords